Tcelna™ (formerly Tovaxin®) is a novel T-cell immunotherapy that has been granted Fast Track designation by the U.S. FDA for the Secondary Progressive MS (SP-MS) indication. Opexa is currently conducting a Phase IIb clinical trial of Tcelna, the Abili-T trial, in SP-MS patients. In addition, Opexa has previously completed a Phase IIb clinical trial in Relapsing Remitting MS (RR-MS) patients and has received endorsement from the U.S. FDA to proceed to Phase III pivotal trials in RR-MS. Opexa continues to evaluate its plans for RR-MS while maintaining its current focus on the SP-MS clinical trial.

For patient inquiries, please send an email to, or call 281.775.0600.